Gianfranco Calogiuri, Lene H Garvey, Eustachio Nettis, Paolo Romita, Elisabetta Di Leo, Riccardo Caruso, Lavjay Butani, Caterina Foti
BACKGROUND: Antifungal azoles are the first-line agents used to treat topical and, above all, systemic mycosis. The latter could be life-threating infections in immunocompromised patients. Chemotherapeutic antibiotics, including antifungal azoles, may induce hypersensitivity reactions; however, such immunologic adverse reactions have not been defined and carefully investigated. OBJECTIVE: The study aims to provide an update on the evaluation and diagnosis of skin allergy to azole antifungal agents...
2019: Recent Patents on Inflammation & Allergy Drug Discovery